Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered paper session - Translational research

1704 - Plasma cell-free DNA (cfDNA) assays for early multi-cancer detection: the Circulating Cell-Free Genome Atlas (CCGA) study

Date

20 Oct 2018

Session

Proffered paper session - Translational research

Topics

Translational Research

Tumour Site

Presenters

Minetta Liu

Citation

Annals of Oncology (2018) 29 (suppl_8): viii14-viii57. 10.1093/annonc/mdy269

Authors

M.C. Liu1, E. Klein2, E. Hubbell3, T. Maddala3, A.M. Aravanis3, J.F. Beausang4, D. Filippova4, S. Gross4, A. Jamshidi4, K. Kurtzman4, L. Shen4, N. Zhang4, O. Venn4, J. Yecies4, S. Patel4, D.A. Smith5, T. Yeatman6, M. Seiden7, A. Hartman4, G. Oxnard8

Author affiliations

  • 1 Division Of Medical Oncology, Department Of Oncology, Mayo Clinic Cancer Center, 55905 - Rochester/US
  • 2 Glickman Urological And Kidney Institute, Cleveland Clinic, 44195 - Cleveland/US
  • 3 Clinical Development And Medical Affairs, GRAIL, 94025 - Menlo Park/US
  • 4 Research And Development, GRAIL, Inc., 94025 - Menlo Park/US
  • 5 Research, Compass Oncology, 98684 - Vancouver/US
  • 6 Smc Division Of Surgery, Gibbs Cancer Center and Research Institute, 29303 - Spartanburg/US
  • 7 Research And Development, US Oncology Research, 77380 - The Woodlands/US
  • 8 Medicine, Dana-Farber Cancer Institute, 2215 - Boston/US
More

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 1704

Background

A noninvasive cfDNA blood test detecting multiple high-mortality cancers at early stages when treatment is more likely effective could decrease cancer mortality. CCGA (NCT02889978) is a prospective multi-center observational study to develop a plasma cfDNA-based multi-cancer detection assay.

Methods

Prospectively collected clinically evaluable samples (N = 2402) from non-cancer controls (C) and participants with newly diagnosed untreated cancer (pts; 20 tumor types, all stages) were divided into training (n = 1458; 580 C, 878 pts) and test (n = 944; 368 C, 576 pts) sets and analyzed as a preplanned substudy. Prototype sequencing assays included paired cfDNA/white blood cell (WBC, 60000X) targeted sequencing, paired cfDNA/WBC whole genome sequencing (30X), cfDNA whole genome bisulfite sequencing (WGBS, 30X). Sensitivity was estimated at 98% specificity. Cancers with >5 pts in training and test are reported.

Results

Overall, pts (all stages) and C had similar age, smoking status, and gender. WGBS returned the highest sensitivity and is included here; results were consistent across the targeted, WGS, and WGBS assays, and will be reported in full. WBC signal was used to correct for clonal hematopoiesis. Stage I-IV cancer detection was consistent in training and test sets. In training, cancer-specific sensitivities (high-signal cancers) ranged from 54-92% and will be reported in detail. In individual cancers in the test set, numbers and sensitivity (95% CI) were: 22 hormone receptor negative breast (36%, 17-59), 45 colorectal (60%, 44-74), 7 esophageal (43%, 10-82), 12 head & neck (50%, 21-79), 15 hepatobiliary (73%, 45-92), 47 lung (70%, 55-83), 22 lymphoma (64%, 41-83), 7 ovarian (71%, 29-96) and 23 pancreatic (74%, 52-90). Results were also consistent between training and test sets in stage I-III and stage IV cancers.

Conclusions

A cfDNA-based blood test detected multiple cancers at various stages consistently in training and test sets. This approach is promising as a multi-cancer early detection test, including for high mortality unscreened cancers where stage shift can impact mortality. Further assay and clinical development of a multi-cancer cfDNA test in large-scale clinical studies, including CCGA, is ongoing.

Clinical trial identification

NCT02889978.

Legal entity responsible for the study

GRAIL, Inc.

Funding

GRAIL, Inc.

Editorial Acknowledgement

Writing support provided by Megan P. Hall, PhD (GRAIL, Inc., Menlo Park, CA).

Disclosure

M.C. Liu: Advisory board member: GRAIL, Inc. E. Klein: Consultant: GRAIL Inc., GenomicHealth, GenomeDx. E. Hubbell: Employee: GRAIL, Inc. with options to hold stock; Stock: ThermoFisher. T. Maddala, A.M. Aravanis, J.F. Beausang, D. Filippova, S. Gross, L. Shen, N. Zhang, O. Venn, J. Yecies, S. Patel, A-R. Hartman: Employee: GRAIL, Inc. with options to hold stock in the company. A. Jamshidi, K. Kurtzman: Employee: GRAIL, Inc. with options to hold stock in the company; Stock: Illumina. M. Seiden: Employee and stocks: McKesson. G.Oxnard: Advisory board member, consultant: Inivata; Honorarium: Guardant Health, Sysmex, BioRad; Consultant: DropWorks, AstraZeneca, GRAIL, Inc. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.